Showing 21-30 of 1537 results for "".
- Leo Pharma's Adbry Reduces S. aureus Skin Colonization in Kids With ADhttps://practicaldermatology.com/news/leo-pharmas-adbry-reduces-s-aureus-skin-colonization-in-kids-with-ad/2461616/Leo Pharma’s Adbry (tralokinumab-ldrm) significantly reduced the abundance of Staphylococcus aureus in the lesional and non-lesional skin of adolescents with atopic dermatitis (AD) after 16 weeks, according to new data presented at the American Academy of Dermatology (AAD) 2023 Annual Meeting. At…
- EMA Accepts Marketing Authorization Applications for UCB's Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritishttps://practicaldermatology.com/news/ema-accepts-marketing-authorization-applications-for-ucbs-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis/2461354/The European Medicines Agency (EMA) has accepted for regulatory review the two marketing authorization applications for UCB's bimekizumab for the treatment of adult patients with active psoriatic arthritis (PsA), and adult patients with active axial spondyloarthritis (axSpA). “These two regulatory…
- Artemis Health, Zerigo Health Partner to Help Employers and Health Plans Better Evaluate and Manage Chronic Autoimmune Skin Conditionshttps://practicaldermatology.com/news/artemis-health-zerigo-health-partner-to-help-employers-and-health-plans-better-evaluate-and-manage-chronic-autoimmune-skin-conditions/2461335/Artemis Health and Zerigo Health are joining forces to helps employers, advisors, and health plans evaluate and manage benefits for their members with chronic autoimmune skin conditions such as psoriasis and atopic dermatitis. “Benefits leaders are inundated by hundreds of point solutions, and man…
- Psoriasis, Other Autoimmune Diseases Up Risk for CVDhttps://practicaldermatology.com/news/psoriasis-other-autoimmune-diseases-up-risk-for-cvd/2461323/Earlier research has suggested associations between some autoimmune disorders and a higher risk of cardiovascular disease, and now, a new study shows that nineteen of the most common autoimmune disorders seem to increase risk for developing heart disease. Patients with autoimmune disease have a s…
- First Austrian Skin Cancer Patients Treated with Rhenium-SCT in New Studyhttps://practicaldermatology.com/news/first-austrian-skin-cancer-patients-treated-with-rhenium-sct-in-new-study/2461110/The first Austrian patients have been treated in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT– for the treatment of non-melanoma skin cancer), according to OncoBeta GmbH. "This is an important step for better understanding efficacy and patient outcomes…
- Updates from EADV: Cosentyx Autoinjector, Genetic Variants Linked to Genital Warts, At-Home PDT Shows Promisehttps://practicaldermatology.com/news/updates-from-eadv-cosentyx-autoinjector-genetic-variants-linked-to-genital-warts-at-home-pdt-shows-promise/2460939/• Treatment with Cosentyx®(secukinumab) 300mg in a 2mL autoinjector (UnoReady® pen) was more effective than placebo and achieved high patient satisfaction compared to two 150mg pre-filled syringes, according to Phase 3b data presented at the EADV 30thAnniversary Congress and reported by Novartis. T…
- StrataGraft Reduces Need for Autografting of Deep Partial-Thickness Burnshttps://practicaldermatology.com/news/stratagraft-reduces-need-for-autografting-of-deep-partial-thickness-burns-strata/2460858/Mallinckrodt plc’s StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) may provide a much-needed alternative to autografting for patients with deep partial-thickness burns, a new study shows. Fully 96 percent of the StrataGraft-treated burn sites across…
- FDA Approves Galderma's Restylane Defyne for Chin Augmentationhttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-defyne-for-chin-augmentation/2460676/The U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 2016 by the FDA for mid-to-deep injecti…
- Hoth Therapeutics Gets Greenlight to Start Phase 1b Trial of BioLexa for AD in Australiahttps://practicaldermatology.com/news/hoth-therapeutics-gets-greenlight-to-start-phase-1b-trial-of-biolexa-for-ad-in-australia/2460627/Hoth Therapeutics, Inc. received Human Research Ethics Committee clearance to commence the first cohort of the Phase 1b clinical trial of BioLexa Lotion for the treatment of mild-to-moderate atopic dermatitis (AD) in Australia. BioLexa is a patented, proprietary antimicrobial topical formulation …
- Industry Responds to COVID-19: Cyrex Labs Offers Multiple Autoimmune Reactivity Screenhttps://practicaldermatology.com/news/industry-responds-to-covid-19-pyrex-labs-offers-multiple-autoimmune-reactivity-screen/2460484/With the risks associated with COVID-19 and because those with one autoimmune disease have a 25 percent chance of developing another, specialists say it is critical for those with autoimmune disease to use safety measures, good eating habits, and self-care to avoid contracting this or any virus. …